Clinical Trials Logo
  1. Home
  2. Progression-free Survival
  3. NCT05958849

Advanced Pancreatic Cancer — PaC  

Progression-free Survival Clinical Trial

Official title:
A Single-arm, Open, Single-center Clinical Study of Sovalutinib in Combination With Solutumab and Tegeo in Second and Second Line for Advanced Pancreatic Cancer

Clinical Trial Summary

This study is a single-arm, open, single-center clinical study to observe and evaluate the efficacy and safety of sovalteinib in combination with solutumab and tegeo in second-line and post-line treatment of patients with advanced pancreatic cancer. A total of 30 patients were enrolled in this study, which was divided into 3 phases: screening phase, treatment phase and follow-up phase. During the treatment period, tumor status was evaluated by imaging methods every 6 weeks (±7 days) until disease progression (PD, RECIST 1.1) or death (during patient treatment) or intolerable toxicity, and tumor treatment and survival status after disease progression were recorded. Safety observations included AE, changes in laboratory test values, vital signs, and changes in ECG. In addition, 10 ml of blood was drawn for testing in our laboratory before each treatment and at the time of disease progression before the patients were enrolled, and the exploration of the efficacy-related biomarker BRCA1 was performed by blood samples.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05958849
Study type Interventional
Source Zhejiang Cancer Hospital
Contact
Status Not yet recruiting
Phase Phase 2
Start date August 1, 2023
Completion date July 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04933669 - Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors Phase 2
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Recruiting NCT03742388 - A Genomic Analysis of Evolution of Epithelia Ovarian Tumors
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Recruiting NCT05310357 - Chromosomal Instability in Ovarian Cancer
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting NCT05897749 - Clinical Study on the Effect of Brucea Javanica Oil Emulsion Injection on the Survival of Patients With Advanced Colorectal Cancer Who Failed to Receive Multi-line Treatment Phase 4
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Not yet recruiting NCT04127760 - Efficacy of Postoperative Radiotherapy for Atypical Meningioma Without Venous Sinus Invasion After Gross-total Resection N/A
Completed NCT03359018 - Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma Phase 2
Completed NCT05796700 - Microwave Ablation Versus Laparoscopic Hepatectomy for 3-5cm Hepatocellular Carcinoma N/A
Recruiting NCT06215495 - A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial N/A
Completed NCT00944918 - Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) Phase 3
Recruiting NCT04664244 - Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma Phase 2